Novartis AG
OTC:NVSEF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Novartis AG
OTC:NVSEF
|
CH |
|
ICICI Bank Ltd
F:ICBA
|
IN |
|
R
|
RomReal Ltd
XMUN:3RR
|
BM |
|
D
|
Dunelm Group PLC
F:DFQ
|
UK |
|
Kokuyo Co Ltd
F:KOK
|
JP |
|
S
|
SAP SE
XMUN:SAP
|
DE |
|
B
|
Banco Bilbao Vizcaya Argentaria SA
SWB:BBVA
|
ES |
|
C
|
Coeur Mining Inc
XMUN:CDM1
|
US |
|
S
|
Sixt SE
XHAN:SIX2
|
DE |
|
M
|
Marsh & McLennan Companies Inc
DUS:MSN
|
US |
Intrinsic Value
Is NVSEF undervalued or overvalued?
See the intrinsic value estimate for 
Novartis AG and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Novartis Does
Novartis AG is a global drugmaker that discovers, develops, manufactures, and sells prescription medicines. Its main products are branded treatments for serious illnesses, including cancer, immune diseases, heart and kidney conditions, eye disease, and some rare disorders. It does not sell everyday consumer health products; its business is centered on medicines that doctors prescribe to patients.
- Headquarters
- Switzerland CH
- Employees
- 75 267
- IPO date
- May 7, 2001
Novartis has no economic moat
Patent protection keeps copies of individual Novartis medicines out temporarily, but it does not permanently prevent competitors from taking sales. Generic competition affecting medicines such as Entresto and Tasigna shows why successful products alone do not ensure lasting protection across the company.
Read the full moat analysis
Revenue & Expenses Breakdown
Novartis AG
Earnings Waterfall
Novartis AG
The intrinsic value for Novartis AG (NVSEF) under the Base Case is hidden USD.
Compared with the current market price of 160.35 USD, the stock appears hidden.